Summary & Overview
CPT 90656: Trivalent Influenza Vaccine, Preservative‑Free, 0.5 mL
CPT code 90656 denotes a preservative‑free trivalent influenza vaccine (split virus) supplied as a 0.5 mL intramuscular dose. This vaccine code matters nationally because seasonal influenza immunization is a core public‑health intervention that affects outpatient vaccination workflows, payer coverage policies, and population‑level prevention efforts. Billing accuracy for vaccine codes like 90656 impacts claim adjudication, provider reimbursement, and immunization registries.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what 90656 represents clinically and operationally, common sites of service for administration, and the typical service type. The publication also provides benchmark considerations, coding and billing context, and any recent policy updates affecting influenza vaccine billing nationally. Practical details cover coding specificity for product and dosage, expected use settings, and the implications for claim processing and payer coverage determination.
Data not available in the input for associated taxonomies, ICD‑10 diagnoses, related codes, and payer‑specific coverage rules; those items are noted as unavailable where applicable.
Billing Code Overview
CPT code 90656 describes a preservative‑free trivalent influenza vaccine (split virus) formulated for intramuscular administration. The product is supplied in a 0.5 mL dose and is intended to provide immunization against three influenza virus strains in a single administration.
Service Type: Vaccine administration (intramuscular immunization)
Typical Site of Service: Outpatient clinics, primary care offices, public health clinics, and other ambulatory care settings where routine vaccinations are delivered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 67-year-old patient presents to a primary care clinic during influenza season for routine immunization. The patient has no acute illness and is due for an annual influenza vaccine; after vaccine consent and screening for contraindications (eg, severe egg allergy, prior severe reaction), a preservative‑free trivalent split-virus influenza vaccine is selected. The clinician documents vaccine lot number, manufacturer, administration site (deltoid muscle), route (intramuscular), dosage (0.5 mL), and patient education provided. The workflow includes verification of insurance and eligibility, administration by a licensed nurse or clinician, post‑vaccination observation of 15 minutes for adverse reactions, and entry of the immunization into the electronic medical record and state immunization registry.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier used by payer specifications | Use when no specialty/other modifier is required by payer policy |
11 | Professional component | Use when reporting the professional component separately if applicable (rare for vaccines) |